Full Press Release Details
Immutep Reports Supportive Efficacy Data from the Phase IIb AIPAC Study; Overall Survival Data Expected in Late 2020.
IMMP
Immutep Reports Supportive Efficacy Data from the Phase IIb AIPAC Study; Overall Survival Data Expected in Late 2020
Key Takeaway: Immutep Reports Supportive Efficacy Data from the Phase IIb AIPAC Study; Overall Survival Data Expected in Late 2020
BiopharmaWatch Analysis
From our catalyst data and publicly available data · not financial adviceBest trade, last catalyst
+76%
120-day peak, hindsight
Typical move
5.4%
average across 13 past catalysts
Lead asset
eftilagimod alfa
Phase 3 · Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC)